Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Cytokinetics Charts.

Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Cytokinetics Charts.

Cytokinetics Inc News

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025
Friday 14 February 2025 (5 days ago) • GlobeNewswire Inc.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 13 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 12 February 2025 (1 week ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Wednesday 12 February 2025 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 11 February 2025 (1 week ago) • Edgar (US Regulatory)

Cytokinetics Names Robert E. Landry to Board of Directors
Tuesday 11 February 2025 (1 week ago) • GlobeNewswire Inc.

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Thursday 6 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 5 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 5 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm
Friday 31 January 2025 (3 weeks ago) • PR Newswire (US)

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program
Thursday 30 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
Tuesday 21 January 2025 (4 weeks ago) • GlobeNewswire Inc.

More Cytokinetics Inc News Articles

TRIUNFO PART ON

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions